BioCryst Adds $350 Million in New Financing with Royalty Pharma and OMERS Capital Markets
22 nov. 2021 07h00 HE
|
BioCryst Pharmaceuticals, Inc.
—Provides funding for BCX9930/oral Factor D program across multiple indications— —Agreements supported by strength of ORLADEYO® (berotralstat) launch and confidence in future opportunity— NEW YORK,...